# Lopinavir (LPV) Dose Reduction

> **NCT01159275** · PHASE1,PHASE2 · COMPLETED · sponsor: **The HIV Netherlands Australia Thailand Research Collaboration** · enrollment: 20 (actual)

## Conditions studied

- HIV-1 Infections

## Interventions

- **DRUG:** Generic LPV/r and Aluvia (pharmacokinetics)
- **DRUG:** Aluvia and Generic LPV/r (pharmacokinetics)

## Key facts

- **NCT ID:** NCT01159275
- **Lead sponsor:** The HIV Netherlands Australia Thailand Research Collaboration
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2020-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01159275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01159275, "Lopinavir (LPV) Dose Reduction". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01159275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*